Company Description
Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia.
Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies.
The company has a research and collaboration agreement with the University of Jaén, to undertakes the research activities for the POP1 Program and the University of Granada to develop a synthetic recombinant version of PRP.
The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017.
Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.
| Country | Australia |
| Founded | 2007 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2 |
| CEO | James Nathanielsz |
Contact Details
Address: 302, 6 Butler Street Camberwell, VIC 3124 Australia | |
| Phone | 61 3 9882 0780 |
| Website | propanc.com |
Stock Details
| Ticker Symbol | PPCB |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001517681 |
| CUSIP Number | 74346N404 |
| ISIN Number | US74346N4043 |
| Employer ID | 33-0662986 |
Key Executives
| Name | Position |
|---|---|
| James Nathanielsz | Chief Executive Officer and Executive Chairman |
| Dr. Julian Norman Kenyon ChB, M.D., MB | Chief Scientific Officer and Director |
| Jeannine Zimmerman | Chief Financial Officer |
| Prof. Klaus Kutz M.D. | Chief Medical Officer and Member of Scientific Advisory Board |